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OBJECTIVE: The objective of this selective EBM review is to determine whether or not is 
liraglutide effective for weight loss in adults who are overweight or obese compared to placebo.  
 
STUDY DESIGN: Review of three double-blind, randomized controlled trials published after 
2010.  
 
DATA SOURCES: All three English language, double-blind, randomized controlled trials were 
found using PubMed. All three RCT’s were published in peer reviewed journals.  
  
OUTCOMES MEASURED: The outcome measured was loss of 7% or more of body weight 
from baseline in the study by Sun et al., and loss of greater than 10% of body weight from 
baseline in the studies by Pi-Sunyer et al. and Davies et al.  
 
RESULTS:  The RCT performed by Davies et al. showed 25.2% of subjects in the liraglutide 
3.0mg group lost more than 10% of baseline body weight compared to 6.7% in the placebo 
group (p< 0.001). The RCT performed by Sun et al. showed 54% of subjects in the liraglutide 
1.8mg group lost 7% of baseline body weight compared to 4% in the placebo group (p< 0.001).  
The RCT performed by Pi-Sunyer et al. showed 33.1% of subjects in the liraglutide 3.0mg 
group lost more than 10% of baseline body weight compared to 10.6% in the placebo group 
(p< 0.001).   
 
CONCLUSIONS: The results of all three RCT’s included in this review indicate that the use of 
liraglutide is effective for weight loss in adults. These studies demonstrated that dosages of 
liraglutide 1.8 mg and 3.0 mg worked in reducing body weight from baseline when compared to 
placebo. Future studies should include lower dosages of liraglutide to assess the efficacy they 
have in weight loss. 
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INTRODUCTION  
Obesity is considered a national epidemic and more than 70% of American adults are 
overweight or obese.1  It is well known that Americans weigh more now than they did in the last 
decade.  In 2016, more than 1.9 billion adults (39%), 18 years and older, were overweight, of 
these over 650 (13%) million were obese.2  Being overweight or obese can be caused by high 
calorie intake, poor diet, lack of physical activity, genetics, underlying medical conditions, or 
certain medications. A high BMI can be an indicator of high body fatness. If the BMI is 25.0 to < 
30, it falls within the overweight range and if the BMI is 30.0 or higher it falls within the obese 
range. In 2012, 11 million visits, or an annual visit rate of 49 visits per 1000 persons, to 
physician offices for obesity were made by adults aged 20 and over.3  Weight loss can prevent or 
at least slow down major risk factors of obesity that include adverse cardiac events, diabetes, 
dyslipidemia, sleep-disordered breathing, diastolic dysfunction, joint problems and others, and, 
by doing this, possibly decrease morbidity and mortality in the long term.4 All these 
complications mentioned are a major concern for patients and physician assistants. Physician 
assistants in the primary and hospital setting will encounter patients that are suffering from the 
complications of being overweight or obese and; thus, will have to come forth with a plan to help 
their patients effectively lose weight. Even a modest weight loss of 5 to 10% of the total body 
weight can produce health benefits, such as improvements in blood pressure, blood cholesterol, 
and blood sugar.  
 Obesity not only cost people their health but it comes at a monetary cost as well. It costs  
 
the global economy about $2 trillion annually or 2.8% of global GDP.5  Research suggests that   
 
the percentage of U.S. health spending on treatment of obesity related illnesses in adults climbed  
 
29% between 2001 and 2015.5  Individuals with obesity have 42% higher healthcare costs than
Yadav: Liraglutide and Weight loss 2 
 people of normal weight and each 1-point increase in BMI leads to a 4% increase in medical  
 
costs and a 7% increase in pharmaceutical costs.5  The pharmaceutical cost of a one-month  
 
supply of liraglutide at the target dose of 3.0 mg per day is approximately $1194.6  That cost is  
 
an out of pocket cost without insurance coverage being applied.  
 
Currently, there are a few options available for weight loss, such as healthy lifestyle  
 
changes including heart healthy eating and physical activity, bariatric surgeries including Roux- 
 
en-Y gastric bypass, sleeve gastrectomy, and adjustable gastric banding, and FDA approved  
 
medications including orlistat, lorcaserin, phentermine-topiramate, and liraglutide.7  With  
 
almost half of American adults making an effort to lose weight, the treatment options mentioned  
 
play an effective role in helping them achieve their goals.8  
 
Liraglutide may be used as an effective agent in helping adults obtain weight loss. It is a  
 
glucagon-like peptide 1 (GLP-1) analog, with 97% homology to human GLP-1 and a therapeutic  
 
potential for both obesity and type 2 diabetes owing to its dual benefits on body weight and  
 
glycemic control.9  GLP-1 analogs like liraglutide not only suppress glucagon but they induce  
 
satiety which leads to reducing appetite and food intake and; thus, subsequent weight reduction.  
 
 OBJECTIVE  
 
The objective of this systematic review is to determine whether or not is liraglutide  
 
effective for weight loss in adults who are overweight or obese compared to placebo.    
METHODS  
 The criteria used for the selection of the three studies included adults. The three studies in  
 
this review were found by searching the PubMed database. The keywords used for this search  
 
were “liraglutide” and “weight loss”. The three articles were chosen for this review because they  
 
proved relevant to the clinical question and the outcomes were measured by Patient-Oriented
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Evidence that Matters. The inclusion criteria included randomized controlled trial, clinical trial,  
 
studies published after 2010, humans, and English language. Exclusion criteria included studies  
 
published earlier than 2010. The three studies that were selected were double-blind, randomized  
 
controlled trials comparing liraglutide to placebo. All three studies were published in the English  
 
language in peer-reviewed journals from 2013 to 2015. The statistics used included RBI, ABI,  
 
NNT, and p-values. 
 
The intervention evaluated in the Sun et al. study was once-daily subcutaneous injections  
 
of liraglutide 1.8 mg  compared to placebo. The interventions evaluated in Pi-Sunyer et al. and  
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Table 1. Demographics and Characteristics of Included Studies 











846  18 Adults aged 18 
with a stable 
body weight, 
BMI of 27 
kg/m2, 
diagnosed with 
type 2 diabetes 
treated with diet 
and exercise 
alone or in 
combination 
with 1-3 oral 
hypoglycemic 
agents 
Treatment w/ any 
antidiabetic drug 
other than 
metformin w/in last 




for obesity, current 
participation in wt. 
loss program, diet 
attempts using 
herbal supplements, 
history of MEN 











by 0.6 mg 







68 40-70 Men and 
women, age 40-
70 years, BMI 
of 27-40 kg/m2 
with prediabetes 
& required to 
have a stable 
weight ( 5% 
reported 
change) in the 
previous 3 
months 
DM2, use of meds 
that can affect carb 
metabolism or 
promote wt. loss, 




hx of medullary 
carcinoma or MEN 
type 2, and known 









weekly to max 







3731  18  Adults aged 
18, stable body 
weight, BMI of 
at least 30 kg/m2 
or a BMI of at 
least 27 kg/m2 if 




DM1 or DM2, meds 
that cause clinically 
significant weight 
gain/loss, previous 
bariatric surgery, hx 
of pancreatitis, hx 
of psychiatric d/o, 
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OUTCOMES MEASURED 
 
 The outcome measured in all three studies was percentage of body weight lost from  
 
baseline. In the Sun et al. study the outcome measured was loss of greater than or equal to 7% of  
 
body weight from baseline. The subjects were weighed at baseline and then at the completion of  
 
the 14 week treatment.10  In the Pi-Sunyer et al. and Davies et al. studies the outcome measured  
 
was loss of greater than 10% of body weight from baseline. In the Pi-Sunyer et al. study subjects  
 
were evaluated every 2 weeks until week 8, then every 4 weeks until week 44, and then again at  
 
weeks 50, 56, 58, 60, 64, 68, and 70.11  In the Davies et al. study body weight was measured at  
 




In all three studies subjects were randomly chosen to receive treatment to lose  
 
bodyweight.  The Davies et al. study focused on overweight or obese adults aged 18 years and  
 
older over a 56 week trial. Eligible subjects were randomly assigned, in a 2:1 ratio, to receive  
 
once daily subcutaneous injections of liraglutide at a starting dose of 0.6 mg that was increased  
 
in increments of 0.6 mg weekly over 4 weeks to the treatment dose.9 This trial used a modified  
 
intent-to-treat analysis and subjects were selected based on inclusion/exclusion criteria noted in  
 
Table 1 of which 423 were randomized to liraglutide and 212 to placebo; however, 324 subjects  
 
in the liraglutide group and 140 subjects in the placebo group completed the 56 week trial.9 At  
 
the conclusion of the trial, from a mean baseline body weight of 105.7 kg for liraglutide 3.0 mg  
 
and 106.5 kg for placebo mean weight losses of 6.0% (6.4 kg) and 2.0% (2.2 kg) were seen.9 In  
 
the liraglutide group, 25.2% of subjects lost more than 10% of their body weight compared to  
 
6.7% of subjects in the placebo group (Table 2).9  Between groups, there was a statistically  
 
significant difference, with p < 0.001 (Table 2).9 The estimated treatment difference was 18.5%
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 [95% CI, 12.7% to 24.4%].9 This study was presented in dichotomous form and the relative  
 
benefit increase was 2.761, the absolute benefit increase was 0.185, and the number needed to  
 




The Sun et al. study compared liraglutide to placebo in adults with a BMI of 27-40 kg/m2  
 
aged 40-70 years over a 14 week trial.  Subjects were block-randomized by sex and BMI (<31  
 
vs. 31 kg/m2) to receive a starting dose of liraglutide 0.6 mg once daily by subcutaneous  
 
injection; the dose was titrated by 0.6 mg weekly to a maximum dose of 1.8 mg or placebo once  
 
daily by subcutaneous injection.10 Sixty-nine individuals qualified for the study based on the  
 
inclusion/exclusion criteria noted in Table 1 of which one withdrew from the study before  
 
randomization.10  Eleven out of 35 individuals assigned to liraglutide discontinued participation  
 
in the study compared with 6 out of 33 assigned to placebo (P = 0.26); 8 out of 11 individuals  
 
using liraglutide discontinued participation due to adverse events compared with none assigned  
 
to placebo (P = 0.009).10 Adverse events included intolerable gastrointestinal side effects (n = 3),  
 
injection site reaction (n = 2), pneumonia (n = 1), gallstone (n = 1), and fall (n = 1).10 Thus, 24  
 
subjects were randomized to the liraglutide group and 27 subjects assigned to the placebo group.  
 
All subjects tolerated the 1.8 mg dose except two liraglutide subjects who required a dose  
 
reduction down to 1.2 and 0.6 mg, respectively, and one placebo subject who required a dose  
 
reduction down to 1.2 mg.10 At the end of the study it was evaluated that subjects randomized to  
 
the liraglutide group lost twice as much weight as those assigned to the placebo group (6.8 vs 3.3  
 
kg; P < 0.001).10 In the liraglutide group, 54% of subjects lost greater than or equal to 7% of  
 
baseline body weight compared to 4% of subjects in the placebo group (Table 2.)10  Between the  
 
groups, there was a statistically significant difference, with p < 0.001 (Table 2).10  The estimated  
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treatment difference was -6.8 kg [95% CI, -7.8kg to -5.9kg].10 This study was presented in  
 
dichotomous form and the relative benefit increase was 12.5, the absolute benefit increase was  
 
0.5, and the number of patients who need to be treated to achieve one additional good outcome  
 




The Pi-Sunyer et al. study focused on adults with a BMI of 30 kg/m2 or higher or 27  
 
kg/m2 or higher if they had treated or untreated dyslipidemia or hypertension aged 18 years or  
 
older over a 56 week trial. Eligible subjects were randomly assigned, in a 2:1 ratio, to receive  
 
once daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6 mg  
 
increments to 3.0 mg, or placebo.11 A total of 3731 patients were selected based on the  
 
inclusion/exclusion criteria noted in Table 1 of which 2487 were randomized to liraglutide and  
 
1244 to placebo. In the liraglutide group, 246 of 2487 (9.9%) withdrew due to adverse events  
 
compared to 47 of 1244 (3.8%) in the placebo group; 23 of 2487 (0.9%) in the liraglutide  
 
withdrew due to ineffective therapy compared to 36 of 1244 (2.9%); other subjects withdrew  
 
their consent.11 Thus, a total of 1789 patients (71.9%) in the liraglutide group, as compared with  
 
801 patients (64.4%) in the placebo group, completed 56 weeks of treatment.11 At the end of the  
 
study, subjects in the liraglutide group lost a mean of 8.0  6.7% (8.4  7.3 kg) of body weight  
 
compared to 2.6  5.7% (2.8  6.5 kg) in the placebo group.11 In the liraglutide group, 33.1% of  
 
subjects lost more than 10% of their body weight compared to 10.6% of subjects in the placebo  
 
group (Table 2).11 Between groups, there was a statistically significant difference, with p < 0.001  
 
(Table 2).11 The estimated treatment difference was -5.6 kg [95% CI, -6.0 to -5.1].11 This study  
 
was also presented in dichotomous form and the relative benefit increase was 2.123, the absolute  
 
benefit increase was 0.225, and the number needed to treat was 5. Adverse events were more  
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commonly seen in subjects in the liraglutide group that consisted of gastrointestinal effects. 
 
Table 2. Percentage of Bodyweight Lost and p-value by Study 
Study 
 
Liraglutide  Placebo P-value 
Davies et al. 
 
25.2% lost >10% weight 6.7% lost >10% weight <0.001 
Sun et al. 
 
54% lost 7% weight 4% lost 7% weight <0.001 
Pi-Sunyer et al. 
 
33.1% lost >10% weight 10.6% lost >10% weight  <0.001 
 
Table 3. Calculations for Treatment by Study 
Study CER EER RBI ABI NNT 
Davies et al. 0.067 0.252 2.761 0.185 6 
Sun et al. 0.04 0.54 12.5 0.5 2 
Pi-Sunyer et 
al.  
0.106 0.331 2.123 0.225 5 
 
DISCUSSION  
   
Based on these three studies, liraglutide is effective at lowering body weight and is, in  
 
fact, superior to placebo. Not only did liraglutide reduce bodyweight, it was effective in  
 
improving insulin resistance, systolic blood pressure, glucose and triglyceride levels according to  
 
the Sun et al. study. One flaw with this particular study, though, was the short duration of the  
 
trial which only lasted 14 weeks. Another flaw of the Sun et al. study was the small sample size  
 
along with 31% of subjects discontinuing participation from the liraglutide group. Pi-Sunyer et  
 
al. found liraglutide to be effective in reducing bodyweight along with decreasing waist  
 
circumference and inflammatory markers. The limitation with this study was the use of last- 
 
observation-carried-forward imputation in the analyses.11 All three studies had limitations that,  
 
most likely, affected the amount of weight lost by advising the subjects to exercise and diet. The  
 
Sun et al. study instructed the subjects to eat a moderate carbohydrate diet with 43%  
 
carbohydrate, 42% fat (< 7 saturated fat) and 15% protein and to decrease total caloric intake by  
 
500 kcal/day.10 In the Pi-Sunyer et al. study both groups received counseling on lifestyle 
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modification.11 In the Davies et al. study the subjects were encouraged to follow a diet  
 
containing a maximum of 30% fat, 50% carbohydrate, with a 500 kcal/day reduction and an  
 
exercise program that involved > 150 min/week of brisk walking.9 
 
To continue, even though all three studies proved liraglutide to be effective at reducing  
 
bodyweight, it comes with a host of adverse events, contraindications, and warnings on use.  
 
Some of the contradictions of liraglutide include a personal or family history of medullary  
 
thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, hypersensitivity to  
 
liraglutide or any product components, and pregnancy.12 The FDA has listed the following  
 
warnings with the use of liraglutide thyroid C-cell tumors, acute pancreatitis, acute gallbladder  
 
disease, serious hypoglycemia which can occur with the concurrent use of sulfonylurea, heart  
 
rate increase, renal impairment, hypersensitivity reactions, such as anaphylactic reactions and  
 
angioedema, suicidal behavior and ideation.12 The FDA states the most common adverse  
 
reactions, reported in greater than or equal to 5% are: nausea, hypoglycemia, diarrhea,  
 
constipation, vomiting, headache, decreased appetite, dyspepsia, fatigue, dizziness, abdominal  
 
pain, and increased lipase, which has also been observed in all three of the studies.  
 
CONCLUSION  
 The three studies in this review provide enough evidence to prove that liraglutide is  
 
effective for weight loss in adults who are overweight or obese compared to placebo. Irrespective  
 
of the dose used, it was shown that liraglutide reduced bodyweight from baseline. Due to the  
 
adverse event profile of liraglutide, long term studies should assess the risk-benefit ratio, which  
 
may lead to future studies assessing the effectiveness of low dose liraglutide on weight loss for  
 
adults who have had adverse events from the higher dose. Also, future studies should include a  
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broader age range to include children that are overweight or obese. Finally, future studies should  
 
be conducted on subjects that are barred from exercise and diet to assess the full potential of  
 





































1. Andrew S. Why exercise won’t make you lose weight. CNN.  
https://www.cnn.com/videos/health/2018/12/14/exercise-weight-loss-orig-st.cnn. Updated 2019. 
Accessed September 27, 2020.  
 
2. Obesity and overweight. World Health Organization. https://www.who.int/news-room/fact-
sheets/detail/obesity-and-overweight. Updated 2020. Accessed November 30, 2020.   
 
3. Talwalkar A, McCarty F. Characteristics of physician office visits for obesity by adults aged 
20 and over: United states, 2012. NCHS Data Brief. 2016;(237)(237):1-8.  
 
4. Conti CR. Obesity and weight loss. Eur Cardiol. 2018;13(2):93-94. 
doi:10.15420/ecr.2018.13.2.EO1. 
 
5. Obesity in america. Asmbs.org Website. https://asmbs.org/resources/obesity-in-america. 
Updated 2018. Accessed September 26, 2020.   
 
6. Whitten JS. Liraglutide (saxenda) for weight loss. Am Fam Physician. 2016;94(2):161-166. 
 
7. Munoz-Mantilla D. Top weight loss medications. obesitymedicine.org 
Website. https://obesitymedicine.org/weight-loss-medications/. Updated 2020. Accessed 
September 27, 2020.  
 
8. Kaplan J. Half of americans are trying to lose weight, including many who are not overweight, 
CDC reports. CommonHealth. 
https://www.wbur.org/commonhealth/2018/07/12/half-americans-lose-weight-cdc. Updated 
2018. Accessed September 27, 2020.  
 
9. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients 
with type 2 diabetes. JAMA. 2015;314(7):687. doi:10.1001/jama.2015.9676.  
 
10. Sun H. K, Fahim A, Cindy L, et al. Benefits of liraglutide treatment in overweight and obese 
older individuals with prediabetes. Diabetes Care. 2013(10):3276. doi:10.2337/dc13-0354.  
 
11. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of 
liraglutide in weight management. NEJM. 2015;373(1):11-22. doi:10.1056/nejmoa1411892.  
 
12. Saxenda (liraglutide [rDNA origin] injection).   
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf. Accessed 
November 30, 2020 
